Patent · US Active

Combined therapy for cystic fibrosis

US9730922B2 · kind B2 · utility

0Cited by

2References

19Claims

0Family size

Assignee

I.E.R.F.C. Europ. Inst. for Cystic. Fibrosis Res. · IT

Inventors

Luigi Maiuri · Milano, IT
Valeria Raia · Milano, IT
Fabio Borella · Milano, IT
Guido Kroemer · Paris, FR

Key dates

Filing date	Aug 4, 2015
Grant date	Aug 15, 2017
Priority date	—
Expiry date	Aug 4, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ΔF508-CFTR mutation, and pharmaceutical compositions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.